Literature DB >> 10935694

Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil. Projeto Praço Onze Study Group.

M Schechter1, R F do Lago, M F de Melo, H W Sheppard, N C Guimarães, R I Moreira, J C Faulhaber, S Batista, L H Harrison.   

Abstract

The study of interventions to prevent HIV transmission requires access to populations with a high rate of HIV transmission. We estimated HIV incidence among heterosexual males and females who were seen at an HIV testing site in Rio de Janeiro, Brazil. Stored sera from individuals who visited the site between March and December 1998 were analyzed using the sensitive/less sensitive (S/LS) assay and a chart abstraction was performed. During the study period, 6353 serum samples were tested. Of those tested, 1203 were found to be HIV-seropositive or indeterminate, of which 1050 (87%) remained available for further testing. In addition, 84 serum samples, representing 63 adults, were found to produce results suggesting early HIV infection. Of these, 14 were heterosexual and female (median age, 38 years), and 19 were heterosexual and male (median age, 25 years). The estimated HIV seroincidence was 1.9 (95% confidence limits (CL), 0.9%-3.9%) and 2.8 (95% CL, 1.4%-5.3%) per 100 person-years among heterosexual women and men, respectively. A survey on willingness to participate in future placebo-controlled HIV vaccine trials in this population indicated that 54.5% and 53.9% of heterosexual women and men, respectively, indicated that they would definitely be willing to participate. We have identified a heterosexual population in Rio de Janeiro with a high rate of HIV transmission willing to participate in placebo-controlled vaccine trials. This study demonstrates the usefulness of the newly described S/LS assay, which allows one to estimate HIV incidence from single serum specimens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935694     DOI: 10.1097/00126334-200006010-00013

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

1.  Demographic profiles of newly acquired HIV infections among adolescents and young adults in the U.S.

Authors:  Anne M Sill; Niel T Constantine; Craig M Wilson; Ligia Peralta
Journal:  J Adolesc Health       Date:  2009-07-08       Impact factor: 5.012

Review 2.  The potential role of biomarkers in HIV preventive vaccine trials.

Authors:  Ellen Maclachlan; Kenneth H Mayer; Ruanne Barnabas; Jorge Sanchez; Beryl Koblin; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

3.  Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil.

Authors:  Carlos A Velasco de Castro; Beatriz Grinsztejn; Valdiléa G Veloso; Francisco I Bastos; José H Pilotto; Mariza G Morgado
Journal:  BMC Infect Dis       Date:  2010-07-28       Impact factor: 3.090

4.  Fishermen as a Suitable Population for HIV Intervention Trials.

Authors:  Zachary A Kwena; Craig R Cohen; Norton M Sang; Musa O Ng'ayo; Jeremiah H Ochieng; Elizabeth A Bukusi
Journal:  AIDS Res Treat       Date:  2010-07-18

5.  Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.

Authors:  M Florencia Etcheverry; Jennifer L Evans; Emilia Sanchez; Eva Mendez-Arancibia; Mercé Meroño; José M Gatell; Kimberly Page; Joan Joseph
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

6.  Comparison among the BED capture enzyme immunoassay test and AxSYM avidity index assay for determining recent HIV infection and incidence in two Voluntary Counselling and Testing Centres in Northeast Brazil.

Authors:  Daniela Medeiros Salustiano; Kledoaldo Oliveira de Lima; Ana Maria Salustiano Cavalcanti; Ricardo Sobhie Diaz; Heloisa Ramos Lacerda
Journal:  Braz J Infect Dis       Date:  2014-04-26       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.